Bacterial Antigen Ingredients TRIZ Cases

TRIS buffer inactivation preserves poliovirus antigens, cutting production costs and increasing global vaccine availability.

A synthetic antigen with a hydroxymethyl linker group immobilized onto a solid substrate enhances antibody recognition.

Soluble HLA-E trimolecular complexes isolate Mycobacterium tuberculosis-specific peptide ligands for precise biomarker discovery.

Lowering fermentation temperature reduces methionine oxidation, maintaining Clostridium botulinum neurotoxin serotype A potency.

Oral vaccine delivery reduces injection reliance while maintaining immunogenicity through protective encapsulation.

Purified 29 kDa Linocin and 22 kDa OMPW antigens overcome bacterial resistance by inducing targeted immune responses.

Engineered Rhodococcus opacus PD630 strains metabolize xylose and glycerol to boost triacylglycerol yields from diverse carbon sources.

Tul4A-C3d fusion protein targets immune cells via TLR2 and CR2 receptors, eliminating exogenous adjuvants for safer tularemia vaccines.

Commensal microbe antigens boost HIV antibody response, reducing heterogeneity in immune responses across individuals.

Polysorbate-stabilized lipidated polypeptides elicit cross-reactive bactericidal titers against diverse Neisseria meningitidis strains.

Composite lysis buffer overcomes milk matrix interference to enable rapid immunochromatographic detection of Streptococcus bacteria.

Engineered E. coli strains with chromosomally integrated methylase genes produce plasmid DNA with controlled CpG methylation levels.

SecY and SecA mutations in Listeria bacteria enhance heterologous antigen secretion while reducing virulence to enable safe cellular immune responses.

Segmented antigen application on porous implants triggers sequential immune activation, resolving inflammatory complications from high-dose biologic stimulants.

Composite vaccine formulation targets active and latent mycobacterial stages, preventing reactivation without triggering drug resistance.

A topical and oral probiotic formulation uses prebiotic lipids to sustain beneficial bacteria on the skin surface.

Pre-conditioned rotavirus vaccine utilizes human serum albumin exposure during growth to enhance stability.

Segmented quench ring assembly removes as a single unit to extend component lifespan against syngas exposure.

Recombinant BCG vaccines express specific M. tuberculosis antigens to resolve cross-reactivity in diagnostic tests.

Killed bacteria immunization reduces insulin resistance and prevents cardiometabolic complications by targeting periodontal dysbiosis.

Engineered bacterial extracellular vesicles enhance oral bioavailability through composite structural protection.

Caspase inhibitors induce necroptosis in dendritic cells to expose ligands, resolving the contradiction between cell death and immune activation.

Attenuated Flavobacterium columnare strains induce protective immunity in fish against virulent infections.

Cell-free IpaB synthesis incorporates non-natural amino acids for conjugation, overcoming low yield of traditional expression methods.

Hydrochloric acid treatment forms bacterial ghosts from gram-positive bacteria.

Memory CD4 T cells enable antibody access to immunoprivileged tissues, resolving delivery bottlenecks for brain and nerve treatments.

Acid-base hydrolysis detaches polysaccharides from cell walls, enabling membrane filtration that removes toxins without chromatography.

Site-directed mutagenesis removes toxic domains from the botulinum neurotoxin, enabling safe prophylactic protection against botulism.

A recombinant beta-herpesvirus expresses NKG2D ligands to activate NK cells and induce a robust immune response.

A recombinant attenuated Edwardsiella vector system synthesizes protective antigens to induce immune responses in fish.

Conserved intracellular LafB antigens provide broad serotype protection against Streptococcus pneumoniae.

Live attenuated Nine Mile phase II bacteria stimulate protective immunity against virulent strains.

Assessing IL-17 production via recombinant BCG identifies reliable Th17 biomarkers, replacing unreliable IFNγ tests to reduce trial duration.

Synthetic serotype 23B polysaccharides resolve incomplete structural knowledge to improve cross-protection against Streptococcus pneumoniae.

Nanoparticles mimic microbial cells via pathogen-associated molecular patterns to suppress TH2 and enhance TH1 responses, treating multiple allergies.

Lipoprotein leader sequences fuse heterologous antigens to OMV membranes, reducing LPS reactogenicity while boosting Th1 immune responses.

Coupling a VHH fragment with an FC fragment extends plasma half-life and stability while preserving antigen specificity for therapeutic use.

Segmented HLA class I and II epitopes elicit long-lived T-cell memory to prevent Q fever without causing reactogenicity in exposed individuals.

A straight-walled vial system enables intact lyophilized cake removal without cracking.

Segmenting the AcfD precursor into fragments resolves solubility limits while maintaining antigenic coverage for pathogenic E. coli vaccines.

Engineered Neisseria gonorrhoeae produces outer membrane vesicles with consistent lipooligosaccharide structures.

Engineered Mycobacterium strains overexpressing diadenylate cyclase enzymes produce signaling nucleotides to enhance vaccine immunogenicity.

A pH-sensitive diblock copolymer encapsulates antigens to form nanoparticles that activate the STING pathway.

Biomarker-based immunoassays identify asymptomatic Salmonella Typhi carriers, resolving low sensitivity in traditional culture methods.

Intranasal nanoemulsions overcome adult vaccine failure by inducing robust Th17 immunity.

Fusion protein combines N-terminal regions of GBS surface proteins to elicit protective immunity against invasive strains without cross-reactions.

Co-administering a PD-1 inhibitor with interferon therapy to restore immune system activity against cancer cells.